Safety data for Lirilumab in combination with Nivolumab or Ipilimumab to be presented at the ESMO 2016 Congress
2016-09-28 · Innate Pharma · original innate-pharma.com ↗
Innate Pharma SA (the “Company” - Euronext Paris: FR0010331421 – IPH) today announces that safety data for two Phase I studies of lirilumab in combination with nivolumab or ipilimumab conducted by Bristol-Myers Squibb in patients with advanced refractory solid tumors will be presented by Dr. Neil H. Segal, Memorial Sloan-Kettering Cancer Center, in a poster at the ESMO 2016 congress (October 7 – 11, 2016) in Copenhagen, Denmark. Lirilumab is Innate Pharma’s anti-KIR antibody partnered with Bristol-Myers Squibb. The abstract is now available on the ESMO website at this link. Subscribe to our newsletter Contact us 117, Avenue de Luminy - BP 30191 13 009 Marseille FRANCE +33 (0)4 30 30 30 30
The release as fetched from its publisher. innate-pharma.com ↗